Fig 1: Effects of CM (1 h and days 4 and 18 after bioprinting) on HUVEC proliferation. (a) HUVEC-proliferation ratios after 24 h and 7 days of treatment with CM obtained from PRP/ALG and PPP/ALG dressings. OD values were normalized to those for control HUVECs, which were cultured under the same conditions in the absence of CM. (b) Box plots showing differences in the median and 25th and 75th percentiles of VEGF/MCP-1 (right) and VEGF/HGF (left) ratios between PRP/ALG and PPP/ALG dressings over time (1 h and days 4 and 18). ** p < 0.01; *** p < 0.001. CM, conditioned media; HUVEC, human umbilical vein endothelial cell; OD, optical density; ALG, alginate; PRP, platelet-rich plasma; PPP, platelet-poor plasma; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; MCP-1, monocyte chemotactic protein 1.
Fig 2: Production/Release of angiogenic and immune modulators by PRP/ALG and PPP/ALG bioprinted dressings at the indicated time points. Box plots showing changes over time (1 h, day 4 and 18) of the median and 25th and 75th percentiles of the released levels of (a) VEGF (pg/mL), (b) HGF (pg/mL), (c) MCP-1 (pg/mL), (d) IL-8 (pg/mL), and (e) ECM-1 (ng/mL). * p < 0.05; ** p < 0.01; *** p < 0.001. ALG, alginate; PRP, platelet-rich plasma; PPP, platelet-poor plasma; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; MCP-1, monocyte chemotactic protein 1; IL-8, interleukin-8; ECM-1, extracellular matrix protein 1.
Supplier Page from RayBiotech for Human HGF ELISA